rawfin.tv
Definium Therapeutics Reports Positive Phase 3 Results for LSD Anxiety Treatment
Top StoriesstocksAI Generated

Definium Therapeutics Reports Positive Phase 3 Results for LSD Anxiety Treatment

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Definium Therapeutics announced successful Phase 3 clinical trial results for its LSD-based formula in treating generalized anxiety disorder. This marks the company's second positive outcome in its Phase 3 program, signaling a potential breakthrough in psychedelic medicine.

BiotechClinical TrialsPsychedelicsMental HealthDrug Development

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks